Shares of Natco Pharma fell nearly 5 per cent Wednesday after the company reported a 26.72 per cent fall in consolidated net profit for the December 2018 quarter.
The company's stock dropped 4.68 per cent to close at Rs 635 on BSE. During the day, it plunged 6.88 per cent to Rs 620.30 -- its 52-week low.
On the NSE, shares went down by 4.79 per cent to close at Rs 634.75.
Drug firm Natco Pharma Tuesday reported a 26.72 per cent fall in consolidated net profit to Rs 159.3 crore for the December 2018 quarter, mainly on account of margin reduction of Oseltamivir in the US market.
It had posted a net profit of Rs 217.4 crore for the corresponding quarter of the previous fiscal, Natco Pharma said in a filing to BSE.
Consolidated total revenue of the company stood at Rs 580 crore for the quarter under consideration as against Rs 573.6 crore for the same period a year ago.
"The decline in profits during the quarter compared to last year was predominantly due to margin reduction of Oseltamivir in the USA market," Natco Pharma said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
